Zhejiang Cheng Yi Pharmaceutical Stock Forum

The market's expectation of poor growth or falling earnings is reflected in the company's P/E ratio. Despite the market's expected 42% growth, the company's recent medium-term growth rates have caused shareholder discomfort and a lower P/E ratio. If these trends persist, a significant share price increase seems unlikely.